<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of celiac disease in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of celiac disease in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of celiac disease in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marisa Stahl, MD, MSCS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edwin Liu, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">B UK Li, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Celiac disease is a condition in which there is abnormal small intestinal mucosa that improves morphologically when treated with a gluten-free diet and relapses when gluten is reintroduced. The disorder is sometimes referred to as "celiac sprue" or "gluten-sensitive enteropathy." A strict gluten-free diet is the only available treatment and should be continued lifelong for those with a confirmed diagnosis of celiac disease.</p><p>The management of celiac disease and its complications are reviewed here. Its pathogenesis, clinical manifestations, and diagnosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children"</a> and  <a class="medical medical_review" href="/z/d/html/100553.html" rel="external">"Diagnosis of celiac disease in children"</a>.)</p><p class="headingAnchor" id="H2195253815"><span class="h1">OVERVIEW OF MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment of the pediatric patient with celiac disease begins with dietary counseling to establish a gluten-free diet. It also includes addressing micronutrient deficiencies, monitoring the response to gluten elimination, and further evaluating patients who do not respond. Long-term management includes monitoring growth and development, surveillance/counselling for cooccurring autoimmune diseases, and monitoring for other potential celiac complications.</p><p>The six key elements in the management of patients with celiac disease can be summarized with the following mnemonic [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>C</strong> - Consultation with a skilled dietitian</p><p class="bulletIndent1"><span class="glyph">●</span><strong>E</strong> - Education about the disease</p><p class="bulletIndent1"><span class="glyph">●</span><strong>L</strong> - Lifelong adherence to a gluten-free diet</p><p class="bulletIndent1"><span class="glyph">●</span><strong>I</strong> - Identification and treatment of nutritional deficiencies</p><p class="bulletIndent1"><span class="glyph">●</span><strong>A</strong> - Access to an advocacy group and/or health behavior support</p><p class="bulletIndent1"><span class="glyph">●</span><strong>C</strong> - Continuous long-term follow-up by a multidisciplinary team</p><p></p><p class="headingAnchor" id="H2"><span class="h1">WHOM TO TREAT</span></p><p class="headingAnchor" id="H3"><span class="h2">Confirmed diagnosis of celiac disease</span><span class="headingEndMark"> — </span>Treatment with a gluten-free diet is recommended for all children who have a confirmed diagnosis of celiac disease. The diagnosis of celiac disease is reinforced if the child responds to the gluten-free diet, with improvement in clinical symptoms and antibody tests.</p><p>In addition, treatment with a gluten-free diet is recommended for patients with dermatitis herpetiformis confirmed by skin biopsy, with or without associated pathology of the small intestinal mucosa. (See <a class="local">'Dermatitis herpetiformis'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Potential celiac disease</span><span class="headingEndMark"> — </span>Potential celiac disease refers to patients who have positive tissue transglutaminase-immunoglobulin A antibodies (tTG-IgA) or endomysial antibody but who have a normal small bowel biopsy [<a href="#rid2">2</a>]. These patients are at an increased risk for celiac disease but cannot be formally diagnosed. There are some challenges with this definition because of the variability in the adequacy of the biopsies taken to exclude active celiac disease. They may or may not have celiac disease. For these patients, management decisions are based on the presence of symptoms and patient preference:</p><p class="bulletIndent1"><span class="glyph">●</span>For children who are truly asymptomatic, a gluten-free diet is not necessary. However, these patients should be monitored with repeat serology and undergo repeat small intestinal biopsy if symptoms develop or if there is higher suspicion of active disease over time. Because a child may not effectively communicate about symptoms that may herald active disease, periodic reevaluation for symptoms and appropriate growth is important. Studies suggest that a majority of children with potential celiac disease will not go on to develop celiac disease even when remaining on a gluten-containing diet [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with symptoms that might be caused by celiac disease, management is unclear. It is reasonable to do a trial of a gluten-free diet, then monitor the response of symptoms and antibody tests, then continue the gluten-free diet if the child's symptoms improve and antibody tests return to normal. For those who do not respond, there is the possibility of a gluten rechallenge and repeat assessment in the future. Undertaking a gluten-free diet in a child with potential celiac disease should be based on joint decision-making between the provider and family.</p><p></p><p>Thus, the presence of symptoms remains the primary determinant of the decision to treat for children with potential celiac disease. Risk factors that predict progression from potential celiac disease to celiac disease include the presence and quantity of intraepithelial lymphocytes, positive anti-endomysial antibody tests, high-risk HLA-DQ genotypes, and presence of high-risk comorbidities [<a href="#rid4">4-7</a>]. Risk factors for celiac disease in the general population are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'Pathogenesis and risk factors'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">DIETARY MANAGEMENT</span></p><p class="headingAnchor" id="H9"><span class="h2">Principles of a gluten-free diet</span><span class="headingEndMark"> — </span>The cornerstone of treatment of celiac disease is the lifelong elimination of gluten in the diet. Consumption of a gluten-free diet requires a major lifestyle change because gluten is contained in many common foods in a Western diet. It is important to provide written information and dietary counseling to improve compliance, ideally from a registered dietitian with expertise in this area [<a href="#rid8">8</a>]. A number of resources are available for patients with celiac disease, including a variety of cookbooks, gluten-free prepared foods, and online organizations (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fceliac.org%2F&amp;token=9WCAAhPcQJC5GR%2BpR9%2B%2FQT4FoXs6eAxYmhqmnS23La4%3D&amp;TOPIC_ID=5907" target="_blank">Celiac Disease Foundation</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.beyondceliac.org%2F&amp;token=h7Ird6MEQJ0ciS3wlIS748%2Bqv4WYD3cdH3GfblS%2BbZ%2Fvpk3l7obdiyDgXGC1gWlK&amp;TOPIC_ID=5907" target="_blank">Beyond Celiac</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnationalceliac.org%2F&amp;token=gO%2FGbJEJg8swtiYwon6z81cskWx3v188ZgJpBcAEabFDn9jEri4rYbGusZOCdvQk&amp;TOPIC_ID=5907" target="_blank">National Celiac Association</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.coeliac.org.uk%2Fhome%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlEaLmDCk5X1JC3wgH4mYaJPgT1gjg4XqDUXfWsA3yodO&amp;TOPIC_ID=5907" target="_blank">Coeliac UK</a>). (See  <a class="medical medical_patient" href="/z/d/html/1999.html" rel="external">"Patient education: Celiac disease in adults (Beyond the Basics)"</a>.)</p><p>As general rules, the following advice can be given to all patients:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Foods to avoid</strong> – Avoid all foods containing wheat, rye, and barley and any food that contains gluten  (<a class="graphic graphic_table graphicRef79790" href="/z/d/graphic/79790.html" rel="external">table 1</a>). Read labels on prepared foods and condiments carefully, paying particular attention to additives such as stabilizers or emulsifiers that may contain gluten.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Foods that are safe</strong> – Alternate starches containing rice, corn, buckwheat, and potatoes can be safely eaten, as can foods with soybean or tapioca flours.</p><p></p><p class="bulletIndent1">Gluten-free labeling may vary in different countries. In the United States and Canada, manufacturers are permitted to label a product "gluten-free" if gluten levels are &lt;20 ppm. This is also the standard set by the international Codex Alimentarius Commission. Accordingly, manufacturers that use this label on their products are responsible for using the claim in an accurate and not misleading manner. In the United States, a "Certified Gluten-Free" label denotes that the product has been tested by a third-party laboratory and meets the criteria, but the US Food and Drug Administration does not specifically endorse or accredit this labeling.</p><p></p><p class="bulletIndent1">A review of the literature by an expert panel concluded that the lower threshold of gliadin intake that can cause mucosal damage is between 10 and 100 mg daily [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oats</strong> – Pure oats, ie, uncontaminated by the other three grains, appear to be safely tolerated by most people with celiac disease, although tolerance varies among patients and depends on the quantity of oats consumed [<a href="#rid8">8</a>]. Our clinical approach is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New diagnosis – For newly diagnosed patients, practice varies among experts. In our practice, we permit certified gluten-free oats from the start and only eliminate oats if patients do not show improvement. Some other experts recommend avoiding oats (including certified gluten-free oats) during the first 6 to 12 months of a gluten-free diet, until the disease is clearly in remission.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In remission – For patients whose disease is in remission after a stringent gluten-free diet, there is no restriction for gluten-free oat consumption. However, it is critical that any oats be certified gluten-free because contamination with even small amounts of other cereals can lead to damage to the intestinal tract [<a href="#rid10">10</a>]. For example, mills that are not dedicated to processing oats alone may cross-contaminate oats with gluten from other grains.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unresponsive or relapsed – For patients who do not respond as anticipated to a gluten-free diet or who relapse after gluten-free oats are reintroduced, we eliminate oats or limit their quantity. This is because there is some uncertainty about the role of oats in a gluten-free diet. First, most studies that examined the safety of oats have included patients with relatively mild disease or whose disease was in remission upon reinstitution of oats in the diet. Second, some patients may have heightened sensitivity to oat prolamins. Third, a few studies suggest that daily intake above 40 to 60 g per day may be associated with disease recurrence, although this is controversial [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Medications (pills) generally contain minimal gluten and do not need to be avoided. Information about gluten-free drugs is available on the internet (eg, <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.glutenfreedrugs.com%2F&amp;token=sQsY3q%2FeCjaueI9YhGWWW1cfAlybACd5v7N6gYK6w8QaD8uRU3HPJZ5%2Fxz4BnSFz&amp;TOPIC_ID=5907" target="_blank">glutenfreedrugs.com</a>).</p><p></p><p>While trace gluten exposures are inevitable, it is also important not to promote hypervigilance, as this may increase child and parental anxiety and disordered eating [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Rationale for strict gluten avoidance</span><span class="headingEndMark"> — </span>A strict gluten-free diet is recommended for all patients with established celiac disease. This is because of the benefit of reducing symptoms for many patients, restoration of normal growth, as well as reduction in long-term adverse health risks. However, it should be recognized that a strict gluten-free diet represents a substantial lifestyle burden. Therefore, in addition to implementing a strict gluten-free diet, dietary counseling should include strategies to minimize the burden of this diet.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits for reducing symptoms</strong> – Many patients experience significant improvement of symptoms on a gluten-free diet. For these patients, the benefit is sufficient to outweigh the burden of adhering to a strict gluten-free diet.</p><p></p><p class="bulletIndent1">However, patients with mild symptoms may feel that the burden of fastidiously avoiding gluten-containing foods outweighs the burden of their symptoms. The perception may be even greater among asymptomatic patients in whom celiac disease was diagnosed based upon antibody screening (ie, testing of first-degree relatives). These patients may be inclined to include small amounts of gluten in their diet. In this case, it is particularly important to discuss the evidence for long-term health risks, as outlined below, so that they can make a fully informed decision.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits for long-term health risks</strong> – The benefit of rigid gluten avoidance has not been conclusively proven, since the natural history of celiac disease in patients who are asymptomatic or have only mild symptoms is unclear. Several arguments favor encouraging strict adherence to a gluten-free diet in most patients with established celiac disease regardless of clinical symptoms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple reports have suggested increased overall mortality (mostly from gastrointestinal malignancies) in patients with celiac disease compared with the general population [<a href="#rid14">14-16</a>]. Several studies have suggested that the risk is decreased in patients who adhere to a gluten-free diet [<a href="#rid17">17-20</a>]. (See  <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ongoing celiac disease activity even without symptoms may still result in the development other long-term complications. For example, patients may have micronutrient deficiencies that may ultimately have clinical consequences (such as bone loss due to vitamin D deficiency) [<a href="#rid21">21</a>]. (See <a class="local">'Screening and prevention of micronutrient deficiencies'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The association between duration of gluten exposure and risk of development of other autoimmune disorders is controversial. While celiac disease is associated with autoimmune diseases such as type 1 diabetes mellitus, Hashimoto thyroiditis, and Graves disease [<a href="#rid22">22-24</a>], the data are discordant and coexistence of autoimmunity may be related to shared genetic predisposition rather than triggered by gluten itself. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'High-risk groups'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mothers with untreated celiac disease are at increased risk for having low birth weight newborns and preterm births [<a href="#rid25">25,26</a>].</p><p></p><p class="headingAnchor" id="H1059752418"><span class="h2">Other dietary counseling</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General nutrition</strong> – Each patient's overall nutritional status should be considered so that nutritional and caloric deficiencies can be adequately supplemented. Patients with the classic presentation of celiac disease may be malnourished; their nutritional status typically improves rapidly after a gluten-free diet is initiated. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on '"Classical" gastrointestinal symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dairy</strong> – For some patients, avoiding dairy products initially may provide symptomatic relief because many patients with celiac disease have secondary lactose intolerance. Lactose can usually be added back to the diet by three to six months (when mucosal healing can be expected) and continued as tolerated. (See  <a class="medical medical_review" href="/z/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fiber</strong> – A gluten-free diet may be low in fiber and may induce troublesome constipation. This usually responds to the addition of dietary fiber such as from <a class="drug drug_pediatric" data-topicid="12749" href="/z/d/drug information/12749.html" rel="external">psyllium</a> or inulin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone health</strong> – Bone loss (principally osteopenia and less often osteoporosis) is common in celiac disease and can occur in patients without gastrointestinal symptoms [<a href="#rid21">21,27-29</a>]. Much of the bone loss is related to secondary hyperparathyroidism, which is probably due to vitamin D deficiency. (See  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'Non-gastrointestinal manifestations'</a>.)</p><p></p><p class="bulletIndent1">Children with celiac disease have reduced bone mass at the time of diagnosis, similar to adults with newly diagnosed celiac disease. However, children are more likely than adults to have fully restored bone mass after 6 to 12 months of a gluten-free diet [<a href="#rid30">30-33</a>]. Nutritional counseling should include instruction on age-appropriate intake of calcium and vitamin D [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Screening and prevention of micronutrient deficiencies</span><span class="headingEndMark"> — </span>Patients with newly diagnosed celiac disease should undergo laboratory evaluation for iron deficiency anemia (using a complete blood count and ferritin) and vitamin D deficiency, and any deficiency should be corrected  (<a class="graphic graphic_table graphicRef110592" href="/z/d/graphic/110592.html" rel="external">table 2</a>) [<a href="#rid8">8</a>]. Routine laboratory testing for other nutritional deficiencies is unnecessary, except in patients with very low body weight or other evidence of malnutrition [<a href="#rid35">35</a>].</p><p>We suggest a daily multivitamin for patients with newly diagnosed celiac disease, as suggested by an expert panel [<a href="#rid35">35</a>]. We also encourage patients to continue the supplement indefinitely because a gluten-free diet is associated with certain micronutrient deficiencies [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H13"><span class="h1">MONITORING THE RESPONSE TO A GLUTEN-FREE DIET</span><span class="headingEndMark"> — </span>The rapidity of the response to a gluten-free diet is variable. Approximately 70 percent of patients have noticeable clinical improvement within two weeks [<a href="#rid37">37</a>]. Clinical tools to monitor celiac disease activity and response to the gluten-free diet are rather limited; symptom monitoring and autoantibody decline/resolution are commonly used. Periodic assessment by a skilled dietitian is also necessary to gauge dietary adherence.</p><p>Symptoms generally improve faster than do antibody levels or histology, especially when biopsies are obtained from the proximal intestine. While historical data indicate that mucosal healing rates are 95 percent in children [<a href="#rid38">38</a>], more recent evidence hints that mucosal healing on a gluten-free diet in pediatrics may not be as complete as previously thought [<a href="#rid39">39,40</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Antibody testing</span><span class="headingEndMark"> — </span>Celiac-specific antibodies levels can be measured to monitor the response to a gluten-free diet as a surrogate for celiac disease activity [<a href="#rid8">8</a>]. Antibody levels will decline on a gluten-free diet but may remain abnormal for up to two years, although this may vary based on the assay used for monitoring and the baseline elevation of the antibody level [<a href="#rid41">41,42</a>].</p><p>Tissue transglutaminase-immunoglobulin A antibodies (tTG-IgA) are usually used for this purpose; alternatives include anti-endomysial antibodies or deamidated gliadin peptide-immunoglobulin G antibodies (DGP-IgG). One study suggests that DGP may be slightly more sensitive to gluten exposure [<a href="#rid43">43</a>]. In IgA-deficient patients, tTG-IgG or DGP-IgG antibodies should be used to monitor dietary exposure to gluten [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/100553.html" rel="external">"Diagnosis of celiac disease in children", section on 'Pretesting diet'</a>.)</p><p>Monitoring should be performed as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For all patients, measure levels at three to six months after the start of treatment, then at approximately six month-intervals until normalized after beginning a gluten-free diet. A decrease in the antibody titer, with eventual disappearance in most individuals, is an indirect indicator of dietary adherence and recovery. In one series, 35 percent of children with celiac disease became seronegative for tTG-IgA within six months of beginning a gluten-free diet and 55 percent were seronegative within 12 months [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If symptoms persist or recur after starting a gluten-free diet, repeat the antibody test. A significant rise in antibody levels may indicate that the individual is ingesting gluten (either knowingly or inadvertently) and should prompt careful review of the diet.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For surveillance, measure levels approximately annually to monitor adherence to the gluten-free diet.</p><p></p><p>Although antibody testing is typically used to monitor response to a gluten-free diet, it may not be a reliable predictor of mucosal recovery. In one study of children who had been on a gluten-free diet for at least one year and underwent follow-up intestinal biopsies, approximately one in five (19 percent) had persistent enteropathy (defined by villous blunting or Marsh stage 3 damage), despite good adherence to the diet [<a href="#rid39">39</a>]. tTG-IgA was elevated in 43 percent of children who had persistent enteropathy and 32 percent of children who had mucosal recovery. Approximately one-half of the children with persistent enteropathy were asymptomatic, and the presence of symptoms did not predict enteropathy.</p><p>Very rarely, a patient is diagnosed with celiac disease on the basis of an abnormal intestinal biopsy despite negative results for all celiac-specific antibody tests; the diagnostic steps for such patients are discussed separately (see  <a class="medical medical_review" href="/z/d/html/100553.html" rel="external">"Diagnosis of celiac disease in children", section on 'Pretesting diet'</a>). In such cases, the response to a gluten-free diet could be monitored by changes in symptoms and/or repeat intestinal biopsy. (See <a class="local">'Follow-up biopsy'</a> below and  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'Pathogenesis and risk factors'</a>.)</p><p class="headingAnchor" id="H4261924718"><span class="h2">Monitoring of nutrition and autoimmune disease</span><span class="headingEndMark"> — </span>For all patients, we monitor the following, as indicated in the table  (<a class="graphic graphic_table graphicRef110592" href="/z/d/graphic/110592.html" rel="external">table 2</a>) [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of growth (height, weight, and body mass index)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iron status (by measuring ferritin)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid-stimulating hormone – Patients with celiac disease have substantially increased risk of autoimmune thyroiditis that increases with age (see  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children", section on 'High-risk groups'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aspartate and alanine aminotransferases – Patients with celiac disease have an increased risk of autoimmune hepatitis [<a href="#rid46">46</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin D status (by measuring 25-hydroxyvitamin D)</p><p></p><p>Laboratory testing for type 1 diabetes is not routinely needed but is appropriate for selected patients based on individual risk factors, clinical signs or symptoms, or prior test results. We counsel patients on the signs and symptoms of type 1 diabetes and perform screening if they develop symptoms.</p><p class="headingAnchor" id="H2143150910"><span class="h1">FOLLOW-UP TESTING FOR SELECTED PATIENTS</span></p><p class="headingAnchor" id="H15"><span class="h2">Follow-up biopsy</span><span class="headingEndMark"> — </span>There is ongoing controversy about the need for a follow-up biopsy in patients with clinical improvement, especially with new data to suggest lower rates of mucosal healing in children. (See  <a class="medical medical_review" href="/z/d/html/100553.html" rel="external">"Diagnosis of celiac disease in children", section on 'Diagnosis'</a>.)</p><p>We and many other clinicians <strong>do not</strong> routinely perform a repeat intestinal biopsy in patients with a definite diagnosis of celiac disease. This practice pattern is consistent with guidelines from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition [<a href="#rid44">44</a>]. However, the study cited above raises concerns about this monitoring approach since neither tissue transglutaminase-immunoglobulin A antibodies (tTG-IgA) nor symptoms were predictors of mucosal healing [<a href="#rid39">39</a>]. (See <a class="local">'Antibody testing'</a> above.)</p><p>For children who do not respond as anticipated to the gluten-free diet, we suggest a repeat endoscopy to evaluate for mucosal healing. The timing of repeat endoscopy will vary based on symptoms, gluten-free diet adherence, and antibody patterns. Although histologic improvement is usually seen within two years of being on a gluten-free diet, persistent abnormalities have been described, even in patients with symptomatic improvement [<a href="#rid40">40,47,48</a>]. After checking for dietary noncompliance or inadvertent ingestion of gluten, other causes of villous atrophy should be considered in these patients. (See <a class="local">'Nonresponders'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h2">Gluten rechallenge</span><span class="headingEndMark"> — </span>In the past, a gluten rechallenge was recommended for all patients to confirm the diagnosis of celiac disease. This is no longer required to confirm the diagnosis of celiac disease, consistent with many society guidelines [<a href="#rid8">8,44,49,50</a>]. (See  <a class="medical medical_review" href="/z/d/html/100553.html" rel="external">"Diagnosis of celiac disease in children"</a>.)</p><p>A gluten rechallenge is usually reserved for cases in which the initial diagnosis of celiac disease remains in doubt. This includes children already on a gluten-free diet either without any prior testing for celiac disease or where there is a discrepancy between the antibody testing and the histologic findings on biopsies.</p><p>If the decision is made to perform a gluten rechallenge, a common protocol is to have the patient ingest at least 10 g of gluten per day (an amount contained in four slices of regular bread) for 8 to 12 weeks, followed by endoscopic biopsies. The biopsy should be performed earlier in patients who develop severe symptoms and are unable to tolerate the full duration of rechallenge. This approach also varies among practitioners, with some rechallenges involving as little as 3 g of gluten per day and for as little as two weeks [<a href="#rid51">51</a>]. Some clinicians will also avoid a gluten rechallenge during high-risk periods such as growth spurts. More research is needed to standardize the gluten rechallenge in pediatrics.</p><p>A rare hazard in a gluten rechallenge is the development of fulminant diarrhea, with resulting dehydration, acidosis, and other metabolic disturbances (a condition known as "gliadin shock" or "celiac crisis") [<a href="#rid52">52</a>]. Such patients should be treated with corticosteroids.</p><p class="headingAnchor" id="H17"><span class="h1">IMMUNIZATIONS</span><span class="headingEndMark"> — </span>Patients with celiac disease should follow routine immunization schedules, with the following special considerations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis B vaccine</strong> – It was previously believed that patients with celiac disease may not respond to the hepatitis B vaccine if administered prior to treatment with a gluten-free diet [<a href="#rid35">35,53</a>]. More recent studies have shown that individuals with celiac disease are not at higher risk of nonresponse than is the general population and, more importantly, are not at higher risk of hepatitis B virus infection [<a href="#rid54">54</a>]. However, some clinicians still perform serologic screening to determine the hepatitis B immune status. If found to be nonimmune to the hepatitis B virus, it is recommended that children undergo repeat immunization once they are on a gluten-free diet and are felt to have achieved mucosal healing. (See  <a class="medical medical_review" href="/z/d/html/101483.html" rel="external">"Hepatitis B virus immunization in infants, children, and adolescents", section on 'Postvaccination serology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumococcal vaccines</strong> – Indirect evidence from studies in adults showed that celiac disease is associated with hyposplenism and an increased risk for invasive pneumococcal disease [<a href="#rid55">55-57</a>]. Children with celiac disease have similarly been shown to have increased risk of pneumococcal infection, although the mechanism of this increased risk is less clear [<a href="#rid57">57,58</a>]. Therefore, it is particularly important to ensure that children with celiac disease receive the standard pneumococcal vaccine series during infancy. It might also be reasonable to screen affected children for evidence of hyposplenism with a complete blood count and peripheral smear (eg, "pitted" erythrocytes, Howell-Jolly bodies, and/or thrombocytosis) and to offer the additional vaccine booster to those with evidence of hyposplenism. Such patients also should receive additional meningococcal vaccination, as for other patients with functional asplenia. (See  <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">"Pneumococcal vaccination in children"</a> and  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coronavirus disease 2019 (COVID-19)</strong> – Individuals with celiac disease are not considered to be at higher risk for COVID-19 infection or for more severe disease [<a href="#rid59">59,60</a>]<strong>. Recommendations for COVID-19 vaccination should follow governmental agency guidelines, and there are no contraindications for COVID-19 vaccination in celiac disease. </strong>(See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">NONRESPONDERS</span><span class="headingEndMark"> — </span>The majority of patients with celiac disease respond to a gluten-free diet. Patients who do not respond fall into four main categories:</p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing gluten ingestion due to poor adherence or inadvertent gluten ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent gastrointestinal disorders that are causing similar symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Diseases that mimic the clinical and histologic features of celiac disease</p><p class="bulletIndent1"><span class="glyph">●</span>Refractory celiac disease (adults)</p><p></p><p>Another consideration in incomplete responders or nonresponders is that not all clinical features of celiac disease respond at the same rate. Furthermore, bone loss caused by secondary hyperparathyroidism and peripheral neuropathy may improve only partially despite a gluten-free diet [<a href="#rid30">30</a>]. Complete catch-up growth may not occur in affected children. (See <a class="local">'Dermatitis herpetiformis'</a> below and  <a class="medical medical_review" href="/z/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children"</a>.)</p><p class="headingAnchor" id="H4110209869"><span class="h2">Ongoing gluten ingestion</span><span class="headingEndMark"> — </span>The most common reasons for a lack of response are poor compliance or inadvertent gluten ingestion  (<a class="graphic graphic_table graphicRef79790" href="/z/d/graphic/79790.html" rel="external">table 1</a>). Thus, a meticulous dietary history should be obtained and dietary counseling pursued with an experienced dietitian in patients who have continued symptoms, persistent histologic abnormalities, or persistently elevated serum antibody titers.</p><p>Preliminary studies suggest that monitoring of fecal gluten immunogenic peptides is a sensitive marker for recent (up to six days) gluten exposure and may be useful for monitoring adherence to a gluten-free diet, although commercially available assays do not provide quantitative results [<a href="#rid61">61,62</a>].</p><p>Trace amounts of gluten may be contained in products that are labeled as gluten-free. One study examined gluten exposures by testing foods for gluten and monitoring fecal and urine gluten immunogenic peptides and demonstrated that many adults with excellent adherence still had inadvertent gluten exposures [<a href="#rid63">63</a>]. However, the small amount of gluten contained in these products does not necessarily translate into refractory disease. A study evaluating occult gluten intake (from grain contaminants) among 76 patients on a gluten-free diet estimated that gluten contamination of up to 100 parts per million (up to a total of 30 mg per day) did not result in histologic injury [<a href="#rid64">64</a>]. Interestingly, 13 of 59 naturally gluten-free products and 11 of 24 wheat starch-based gluten-free products contained gluten ranging from 20 to 200 mg/kg. Gluten is a common additive in plastics. In one case report, remission was prevented by exposure to gluten from an orthodontic retainer [<a href="#rid65">65</a>].</p><p>If children have ongoing symptoms and persistent features of celiac disease on repeat biopsies despite apparent good adherence to a gluten-free diet, a time-limited trial of a gluten contamination elimination diet for up to 12 weeks should be considered. This is a very restrictive diet that is intended to eliminate any inadvertent exposures and not for long-term management of celiac disease [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Concurrent gastrointestinal disorders</span><span class="headingEndMark"> — </span>Other diagnoses should be considered in patients who, despite apparent compliance, continue to have symptoms or do not have histologic improvement.</p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant or secondary lactose intolerance is a possible cause of continued diarrhea and flatulence. (See  <a class="medical medical_review" href="/z/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with celiac disease are susceptible to common bowel disturbances such as irritable bowel syndrome, which affects a large proportion of the general population and is characterized by chronic abdominal pain and altered bowel habits. (See  <a class="medical medical_review" href="/z/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A small percentage of patients with celiac disease develop small bowel bacterial overgrowth, which may respond to antibiotics [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/4778.html" rel="external">"Small intestinal bacterial overgrowth: Management"</a>.)</p><p></p><p class="headingAnchor" id="H646555634"><span class="h2">Diseases that mimic celiac disease</span><span class="headingEndMark"> — </span>A number of diseases associated with small bowel villous atrophy also should be excluded in patients with persistent symptoms who do not show histologic improvement  (<a class="graphic graphic_table graphicRef60030" href="/z/d/graphic/60030.html" rel="external">table 3</a>) [<a href="#rid68">68,69</a>]. (See  <a class="medical medical_review" href="/z/d/html/4704.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Refractory celiac disease</span><span class="headingEndMark"> — </span>Refractory celiac disease occurs almost exclusively in adults and very rarely in children. These patients meet all the diagnostic criteria for celiac disease but either no initial response to a gluten-free diet or have an initial response but subsequently develop refractory disease despite rigorous gluten abstinence [<a href="#rid70">70</a>]. The diagnostic workup and management of patients with refractory celiac disease in adults are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4777.html" rel="external">"Management of celiac disease in adults", section on 'Refractory sprue'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">DERMATITIS HERPETIFORMIS</span><span class="headingEndMark"> — </span>Dermatitis herpetiformis is a skin disorder that is closely associated with celiac disease. It is characterized by an itchy papular vesicular eruption usually located symmetrically on the elbows, knees, buttocks, sacrum, face, neck, trunk, and, occasionally, within the mouth  (<a class="graphic graphic_picture graphicRef86751" href="/z/d/graphic/86751.html" rel="external">picture 1</a>) [<a href="#rid71">71</a>]. The predominant symptoms are itching and burning that are rapidly relieved with rupture of the blisters. The vast majority of patients with dermatitis herpetiformis have associated celiac disease (gluten-sensitive enteropathy), but many of these patients have few or no gastrointestinal symptoms. (See  <a class="medical medical_review" href="/z/d/html/15307.html" rel="external">"Dermatitis herpetiformis", section on 'Clinical findings'</a>.)</p><p>Improvement in dermatitis herpetiformis following withdrawal of gluten may be considerably delayed (6 to 12 months) compared with the response of the intestinal manifestations of the disease [<a href="#rid72">72</a>]. As a result, treatment usually includes medical therapy (such as <a class="drug drug_pediatric" data-topicid="13205" href="/z/d/drug information/13205.html" rel="external">dapsone</a>) in addition to gluten avoidance [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/15307.html" rel="external">"Dermatitis herpetiformis", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/15307.html" rel="external">"Dermatitis herpetiformis", section on 'Treatment of children'</a>.)</p><p class="headingAnchor" id="H817315485"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113964.html" rel="external">"Society guideline links: Celiac disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/130048.html" rel="external">"Society guideline links: Dermatitis herpetiformis"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86971.html" rel="external">"Patient education: Gluten-free diet (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1212.html" rel="external">"Patient education: Celiac disease in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whom to treat</strong> – Celiac disease is a genetically determined sensitivity to dietary gluten. Treatment depends on whether the diagnosis is serologically and histologically confirmed and whether the patient has symptoms attributable to the disease. (See <a class="local">'Whom to treat'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Confirmed diagnosis</strong> – For patients with serologically and histologically confirmed celiac disease, treatment is as follows (see <a class="local">'Confirmed diagnosis of celiac disease'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Symptomatic patients</strong> – For patients with symptoms attributable to celiac disease, we recommend a lifelong gluten-free diet (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). A gluten-free diet reduces or eliminates symptoms for most patients, restores normal growth, and may reduce long-term adverse health risks. The diet should be guided by in-depth consultation with an expert dietitian. (See <a class="local">'Rationale for strict gluten avoidance'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Asymptomatic patients</strong> – For patients with few or no symptoms but with histologic evidence of celiac disease, we suggest a gluten-free diet (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The rationale for this weak recommendation is that a gluten-free diet may reduce the risk of long-term complications. However, the certainty of this benefit in asymptomatic patients is low and the dietary regimen may impair quality of life. Thus, some patients may choose to delay initiating a strict gluten-free diet, but this decision should be made in consultation with a gastroenterologist. (See <a class="local">'Confirmed diagnosis of celiac disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>"Potential" celiac disease</strong> – "Potential" celiac disease refers to patients who have positive serologic tests for celiac disease (tissue transglutaminase-immunoglobulin A antibodies [tTG-IgA] or endomysial antibody) but have normal small bowel biopsy. A gluten-free diet is <strong>not</strong> necessary in such patients if they are asymptomatic. However, it is important to ensure that the evaluation included multiple intestinal biopsies since histologic abnormalities can be patchy. These patients should be carefully monitored for growth failure and other symptoms that might suggest active celiac disease, and they should be rebiopsied if symptoms develop. (See <a class="local">'Potential celiac disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Avoid premature initiation of a gluten-free diet</strong> – A gluten-free diet should <strong>not</strong> be initiated prior to serologic testing for celiac disease, because these tests may be falsely negative if performed while on a gluten-free diet. Moreover, a clinical response to a gluten-free diet is not sufficient to establish the diagnosis of celiac disease or of nonceliac gluten-sensitivity. (See <a class="local">'Whom to treat'</a> above and  <a class="medical medical_review" href="/z/d/html/100553.html" rel="external">"Diagnosis of celiac disease in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gluten-free diet</strong> – A gluten-free diet requires strict avoidance of wheat, rye, and barley  (<a class="graphic graphic_table graphicRef79790" href="/z/d/graphic/79790.html" rel="external">table 1</a>). Patients require detailed dietary counseling to improve compliance and avoid common pitfalls in maintaining a gluten-free diet.</p><p></p><p class="bulletIndent1">Pure oats (ie, uncontaminated by the other three grains) appear to be safely tolerated by most people with celiac disease, but tolerance varies. We generally advise that gluten-free oats are safe, and only eliminate oats for patients who do not respond as anticipated to the gluten-free diet. (See <a class="local">'Principles of a gluten-free diet'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring the response</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibody testing</strong> – After establishing a gluten-free diet, specific serologic testing (tTG-IgA) should be repeated approximately every six months until it normalizes. A decrease in the antibody titer indicates adherence to the diet and supports the diagnosis of celiac disease. (See <a class="local">'Antibody testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional testing (selected patients)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Repeat biopsy</strong> – A repeat biopsy is generally not indicated in individuals with an established diagnosis of celiac disease. However, in some situations, a follow-up biopsy to evaluate for mucosal healing may be warranted. (See <a class="local">'Follow-up biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gluten rechallenge</strong> – Rechallenging the patient with gluten is not required to establish a diagnosis of celiac disease. However, gluten rechallenge may be helpful for selected patients in whom the diagnosis remains ambiguous after a trial of a gluten-free diet. (See <a class="local">'Gluten rechallenge'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – All patients with celiac disease should be reevaluated periodically. The evaluation should include assessment of growth, assessment of gastrointestinal and other symptoms associated with celiac disease, and review of the patient's understanding of and compliance with the gluten-free diet  (<a class="graphic graphic_table graphicRef110592" href="/z/d/graphic/110592.html" rel="external">table 2</a>). We repeat tTG-IgA approximately every six months, then annually after it normalizes. We also repeat tTG-IgA in patients with recurrent or persistent symptoms. (See <a class="local">'Monitoring the response to a gluten-free diet'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonresponders</strong> – The majority of patients with celiac disease respond to a gluten-free diet. The most common reasons for lack of response are poor compliance or inadvertent gluten ingestion. (See <a class="local">'Nonresponders'</a> above.)</p><p></p><p class="headingAnchor" id="H3520796069"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ivor D Hill, MD who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">NIH Consensus Development Conference on Celiac Disease. NIH Consens State Sci Statements 2004; 21:1.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62:43.</a></li><li><a class="nounderline abstract_t">Lionetti E, Castellaneta S, Francavilla R, et al. Long-Term Outcome of Potential Celiac Disease in Genetically at-Risk Children: The Prospective CELIPREV Cohort Study. J Clin Med 2019; 8.</a></li><li><a class="nounderline abstract_t">Auricchio R, Mandile R, Del Vecchio MR, et al. Progression of Celiac Disease in Children With Antibodies Against Tissue Transglutaminase and Normal Duodenal Architecture. Gastroenterology 2019; 157:413.</a></li><li><a class="nounderline abstract_t">Sakhuja S, Holtz LR. Progression of pediatric celiac disease from potential celiac disease to celiac disease: a retrospective cohort study. BMC Pediatr 2021; 21:149.</a></li><li><a class="nounderline abstract_t">Paparo F, Petrone E, Tosco A, et al. Clinical, HLA, and small bowel immunohistochemical features of children with positive serum antiendomysium antibodies and architecturally normal small intestinal mucosa. Am J Gastroenterol 2005; 100:2294.</a></li><li><a class="nounderline abstract_t">Kurppa K, Ashorn M, Iltanen S, et al. Celiac disease without villous atrophy in children: a prospective study. J Pediatr 2010; 157:373.</a></li><li><a class="nounderline abstract_t">Rubio-Tapia A, Hill ID, Semrad C, et al. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. Am J Gastroenterol 2023; 118:59.</a></li><li><a class="nounderline abstract_t">Hischenhuber C, Crevel R, Jarry B, et al. Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease. Aliment Pharmacol Ther 2006; 23:559.</a></li><li><a class="nounderline abstract_t">Thompson T. Gluten contamination of commercial oat products in the United States. N Engl J Med 2004; 351:2021.</a></li><li><a class="nounderline abstract_t">Schmitz J. Lack of oats toxicity in coeliac disease. BMJ 1997; 314:159.</a></li><li><a class="nounderline abstract_t">La Vieille S, Pulido OM, Abbott M, et al. Celiac Disease and Gluten-Free Oats: A Canadian Position Based on a Literature Review. Can J Gastroenterol Hepatol 2016; 2016:1870305.</a></li><li><a class="nounderline abstract_t">Wolf RL, Lebwohl B, Lee AR, et al. Hypervigilance to a Gluten-Free Diet and Decreased Quality of Life in Teenagers and Adults with Celiac Disease. Dig Dis Sci 2018; 63:1438.</a></li><li><a class="nounderline abstract_t">Hardwick C. Prognosis in coeliac disease: A Review of Seventy-Three Cases. Arch Dis Child 1939; 14:279.</a></li><li><a class="nounderline abstract_t">Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in celiac disease. Gastroenterology 1989; 97:265.</a></li><li><a class="nounderline abstract_t">Nielsen OH, Jacobsen O, Pedersen ER, et al. Non-tropical sprue. Malignant diseases and mortality rate. Scand J Gastroenterol 1985; 20:13.</a></li><li><a class="nounderline abstract_t">Holmes GK, Prior P, Lane MR, et al. Malignancy in coeliac disease--effect of a gluten free diet. Gut 1989; 30:333.</a></li><li><a class="nounderline abstract_t">Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 2001; 358:356.</a></li><li><a class="nounderline abstract_t">Askling J, Linet M, Gridley G, et al. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002; 123:1428.</a></li><li><a class="nounderline abstract_t">Collin P, Reunala T, Pukkala E, et al. Coeliac disease--associated disorders and survival. Gut 1994; 35:1215.</a></li><li><a class="nounderline abstract_t">Shaker JL, Brickner RC, Findling JW, et al. Hypocalcemia and skeletal disease as presenting features of celiac disease. Arch Intern Med 1997; 157:1013.</a></li><li><a class="nounderline abstract_t">Ventura A, Magazzù G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 1999; 117:297.</a></li><li><a class="nounderline abstract_t">Cosnes J, Cellier C, Viola S, et al. Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol 2008; 6:753.</a></li><li><a class="nounderline abstract_t">Sategna Guidetti C, Solerio E, Scaglione N, et al. Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders. Gut 2001; 49:502.</a></li><li><a class="nounderline abstract_t">Nørgård B, Fonager K, Sørensen HT, Olsen J. Birth outcomes of women with celiac disease: a nationwide historical cohort study. Am J Gastroenterol 1999; 94:2435.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Montgomery SM, Ekbom A. Celiac disease and risk of adverse fetal outcome: a population-based cohort study. Gastroenterology 2005; 129:454.</a></li><li><a class="nounderline abstract_t">Walters JR, Banks LM, Butcher GP, Fowler CR. Detection of low bone mineral density by dual energy x ray absorptiometry in unsuspected suboptimally treated coeliac disease. Gut 1995; 37:220.</a></li><li><a class="nounderline abstract_t">Mustalahti K, Collin P, Sievänen H, et al. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999; 354:744.</a></li><li><a class="nounderline abstract_t">Meyer D, Stavropolous S, Diamond B, et al. Osteoporosis in a north american adult population with celiac disease. Am J Gastroenterol 2001; 96:112.</a></li><li><a class="nounderline abstract_t">Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999; 14:652.</a></li><li><a class="nounderline abstract_t">Mora S, Barera G, Beccio S, et al. A prospective, longitudinal study of the long-term effect of treatment on bone density in children with celiac disease. J Pediatr 2001; 139:516.</a></li><li><a class="nounderline abstract_t">Zanchi C, Di Leo G, Ronfani L, et al. Bone metabolism in celiac disease. J Pediatr 2008; 153:262.</a></li><li><a class="nounderline abstract_t">Gerenli N, Dursun F, Çeltik C, Kırmızıbekmez H. Significant improvement in bone mineral density in pediatric celiac disease: even at six months with gluten-free diet. J Pediatr Endocrinol Metab 2021; 34:341.</a></li><li class="breakAll">United States Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D, Ross AC, Taylor CL, Yaktine AL, Del Valle HB (Eds), National Academies Press, 2011.</li><li><a class="nounderline abstract_t">Snyder J, Butzner JD, DeFelice AR, et al. Evidence-Informed Expert Recommendations for the Management of Celiac Disease in Children. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Di Nardo G, Villa MP, Conti L, et al. Nutritional Deficiencies in Children with Celiac Disease Resulting from a Gluten-Free Diet: A Systematic Review. Nutrients 2019; 11.</a></li><li><a class="nounderline abstract_t">Pink IJ, Creamer B. Response to a gluten-free diet of patients with the coeliac syndrome. Lancet 1967; 1:300.</a></li><li><a class="nounderline abstract_t">Wahab PJ, Meijer JW, Mulder CJ. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118:459.</a></li><li><a class="nounderline abstract_t">Leonard MM, Weir DC, DeGroote M, et al. Value of IgA tTG in Predicting Mucosal Recovery in Children With Celiac Disease on a Gluten-Free Diet. J Pediatr Gastroenterol Nutr 2017; 64:286.</a></li><li><a class="nounderline abstract_t">Veeraraghavan G, Therrien A, Degroote M, et al. Non-responsive celiac disease in children on a gluten free diet. World J Gastroenterol 2021; 27:1311.</a></li><li><a class="nounderline abstract_t">Sansotta N, Alessio MG, Norsa L, et al. Trend of Antitissue Transglutaminase Antibody Normalization in Children With Celiac Disease Started on Gluten-free Diet: A Comparative Study Between Chemiluminescence and ELISA Serum Assays. J Pediatr Gastroenterol Nutr 2020; 70:37.</a></li><li><a class="nounderline abstract_t">Gidrewicz D, Trevenen CL, Lyon M, Butzner JD. Normalization Time of Celiac Serology in Children on a Gluten-free Diet. J Pediatr Gastroenterol Nutr 2017; 64:362.</a></li><li><a class="nounderline abstract_t">Monzani A, Rapa A, Fonio P, et al. Use of deamidated gliadin peptide antibodies to monitor diet compliance in childhood celiac disease. J Pediatr Gastroenterol Nutr 2011; 53:55.</a></li><li><a class="nounderline abstract_t">Hill ID, Fasano A, Guandalini S, et al. NASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related Disorders. J Pediatr Gastroenterol Nutr 2016; 63:156.</a></li><li><a class="nounderline abstract_t">Hogen Esch CE, Wolters VM, Gerritsen SA, et al. Specific celiac disease antibodies in children on a gluten-free diet. Pediatrics 2011; 128:547.</a></li><li><a class="nounderline abstract_t">Villavicencio Kim J, Wu GY. Celiac Disease and Elevated Liver Enzymes: A Review. J Clin Transl Hepatol 2021; 9:116.</a></li><li><a class="nounderline abstract_t">Lee SK, Lo W, Memeo L, et al. Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc 2003; 57:187.</a></li><li><a class="nounderline abstract_t">Selby WS, Painter D, Collins A, et al. Persistent mucosal abnormalities in coeliac disease are not related to the ingestion of trace amounts of gluten. Scand J Gastroenterol 1999; 34:909.</a></li><li class="breakAll">National Institutes of Health Consensus Development Conference Statement. Celiac Disease 2004. Available at: http://consensus.nih.gov/ (Accessed on March 11, 2011).</li><li><a class="nounderline abstract_t">Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 1990; 65:909.</a></li><li><a class="nounderline abstract_t">Leonard MM, Silvester JA, Leffler D, et al. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial. Gastroenterology 2021; 160:720.</a></li><li><a class="nounderline abstract_t">KRAINICK HG, DEBATIN F, GAUTIER E, et al. [Additional research on the injurious effect of wheat flour in celiac disease.I. Acute gliadin reaction (gliadin shock)]. Helv Paediatr Acta 1958; 13:432.</a></li><li><a class="nounderline abstract_t">Ertekin V, Tosun MS, Selimoglu MA. Is there need for a new hepatitıs B vaccine schedule for children with celiac disease? Hepat Mon 2011; 11:634.</a></li><li><a class="nounderline abstract_t">Habash N, Choung RS, Jacobson RM, et al. Celiac Disease: Risk of Hepatitis B Infection. J Pediatr Gastroenterol Nutr 2022; 74:328.</a></li><li><a class="nounderline abstract_t">Corazza GR, Zoli G, Di Sabatino A, et al. A reassessment of splenic hypofunction in celiac disease. Am J Gastroenterol 1999; 94:391.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Olén O, Bell M, et al. Coeliac disease and risk of sepsis. Gut 2008; 57:1074.</a></li><li><a class="nounderline abstract_t">Simons M, Scott-Sheldon LAJ, Risech-Neyman Y, et al. Celiac Disease and Increased Risk of Pneumococcal Infection: A Systematic Review and Meta-Analysis. Am J Med 2018; 131:83.</a></li><li><a class="nounderline abstract_t">Canova C, Ludvigsson J, Baldo V, et al. Risk of bacterial pneumonia and pneumococcal infection in youths with celiac disease - A population-based study. Dig Liver Dis 2019; 51:1101.</a></li><li><a class="nounderline abstract_t">Zhen J, Stefanolo JP, Temprano MP, et al. The Risk of Contracting COVID-19 Is Not Increased in Patients With Celiac Disease. Clin Gastroenterol Hepatol 2021; 19:391.</a></li><li><a class="nounderline abstract_t">Lebwohl B, Larsson E, Söderling J, et al. Risk of Severe Covid-19 in Patients with Celiac Disease: A Population-Based Cohort Study. Clin Epidemiol 2021; 13:121.</a></li><li><a class="nounderline abstract_t">Comino I, Fernández-Bañares F, Esteve M, et al. Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients. Am J Gastroenterol 2016; 111:1456.</a></li><li><a class="nounderline abstract_t">Moreno ML, Rodríguez-Herrera A, Sousa C, Comino I. Biomarkers to Monitor Gluten-Free Diet Compliance in Celiac Patients. Nutrients 2017; 9.</a></li><li><a class="nounderline abstract_t">Silvester JA, Comino I, Kelly CP, et al. Most Patients With Celiac Disease on Gluten-Free Diets Consume Measurable Amounts of Gluten. Gastroenterology 2020; 158:1497.</a></li><li><a class="nounderline abstract_t">Collin P, Thorell L, Kaukinen K, Mäki M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? Aliment Pharmacol Ther 2004; 19:1277.</a></li><li><a class="nounderline abstract_t">Memon Z, Baker SS, Khan A, et al. An orthodontic retainer preventing remission in celiac disease. Clin Pediatr (Phila) 2013; 52:1034.</a></li><li><a class="nounderline abstract_t">Leonard MM, Cureton P, Fasano A. Indications and Use of the Gluten Contamination Elimination Diet for Patients with Non-Responsive Celiac Disease. Nutrients 2017; 9.</a></li><li><a class="nounderline abstract_t">Tursi A, Brandimarte G, Giorgetti G. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol 2003; 98:839.</a></li><li><a class="nounderline abstract_t">Shah VH, Rotterdam H, Kotler DP, et al. All that scallops is not celiac disease. Gastrointest Endosc 2000; 51:717.</a></li><li><a class="nounderline abstract_t">Leonard MM, Lebwohl B, Rubio-Tapia A, Biagi F. AGA Clinical Practice Update on the Evaluation and Management of Seronegative Enteropathies: Expert Review. Gastroenterology 2021; 160:437.</a></li><li><a class="nounderline abstract_t">Trier JS, Falchuk ZM, Carey MC, Schreiber DS. Celiac sprue and refractory sprue. Gastroenterology 1978; 75:307.</a></li><li><a class="nounderline abstract_t">Fry L. Dermatitis herpetiformis. Baillieres Clin Gastroenterol 1995; 9:371.</a></li><li><a class="nounderline abstract_t">Garioch JJ, Lewis HM, Sargent SA, et al. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131:541.</a></li></ol></div><div id="topicVersionRevision">Topic 5907 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17308551" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : NIH Consensus Development Conference on Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22345659" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Oslo definitions for coeliac disease and related terms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30764503" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-Term Outcome of Potential Celiac Disease in Genetically at-Risk Children: The Prospective CELIPREV Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30978358" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Progression of Celiac Disease in Children With Antibodies Against Tissue Transglutaminase and Normal Duodenal Architecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33781221" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Progression of pediatric celiac disease from potential celiac disease to celiac disease: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16181383" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical, HLA, and small bowel immunohistochemical features of children with positive serum antiendomysium antibodies and architecturally normal small intestinal mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20400102" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Celiac disease without villous atrophy in children: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36602836" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16480395" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15525734" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gluten contamination of commercial oat products in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9022420" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lack of oats toxicity in coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27446825" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Celiac Disease and Gluten-Free Oats: A Canadian Position Based on a Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29387990" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hypervigilance to a Gluten-Free Diet and Decreased Quality of Life in Teenagers and Adults with Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21032153" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognosis in coeliac disease: A Review of Seventy-Three Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2744350" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mortality in celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3992161" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Non-tropical sprue. Malignant diseases and mortality rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2707633" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Malignancy in coeliac disease--effect of a gluten free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502314" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mortality in patients with coeliac disease and their relatives: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12404215" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7959226" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Coeliac disease--associated disorders and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9140273" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hypocalcemia and skeletal disease as presenting features of celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10419909" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18255352" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559646" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10484005" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Birth outcomes of women with celiac disease: a nationwide historical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083702" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Celiac disease and risk of adverse fetal outcome: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7557572" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Detection of low bone mineral density by dual energy x ray absorptiometry in unsuspected suboptimally treated coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475193" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Osteopenia in patients with clinically silent coeliac disease warrants screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11197239" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Osteoporosis in a north american adult population with celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10234588" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bone loss in celiac disease is related to secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598597" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A prospective, longitudinal study of the long-term effect of treatment on bone density in children with celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534236" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bone metabolism in celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33675212" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Significant improvement in bone mineral density in pediatric celiac disease: even at six months with gluten-free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33675212" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Significant improvement in bone mineral density in pediatric celiac disease: even at six months with gluten-free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27565547" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evidence-Informed Expert Recommendations for the Management of Celiac Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31337023" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nutritional Deficiencies in Children with Celiac Disease Resulting from a Gluten-Free Diet: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4163509" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Response to a gluten-free diet of patients with the coeliac syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12219789" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28112686" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Value of IgA tTG in Predicting Mucosal Recovery in Children With Celiac Disease on a Gluten-Free Diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33833484" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Non-responsive celiac disease in children on a gluten free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31599818" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Trend of Antitissue Transglutaminase Antibody Normalization in Children With Celiac Disease Started on Gluten-free Diet: A Comparative Study Between Chemiluminescence and ELISA Serum Assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28231071" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Normalization Time of Celiac Serology in Children on a Gluten-free Diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21694536" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Use of deamidated gliadin peptide antibodies to monitor diet compliance in childhood celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27035374" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : NASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21859913" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Specific celiac disease antibodies in children on a gluten-free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33604262" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Celiac Disease and Elevated Liver Enzymes: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12556782" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Duodenal histology in patients with celiac disease after treatment with a gluten-free diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522611" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Persistent mucosal abnormalities in coeliac disease are not related to the ingestion of trace amounts of gluten.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522611" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Persistent mucosal abnormalities in coeliac disease are not related to the ingestion of trace amounts of gluten.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205160" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33130104" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13610260" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : [Additional research on the injurious effect of wheat flour in celiac disease.I. Acute gliadin reaction (gliadin shock)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22140387" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Is there need for a new hepatitıs B vaccine schedule for children with celiac disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34856564" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Celiac Disease: Risk of Hepatitis B Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022635" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A reassessment of splenic hypofunction in celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18270242" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Coeliac disease and risk of sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28801224" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Celiac Disease and Increased Risk of Pneumococcal Infection: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30926284" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Risk of bacterial pneumonia and pneumococcal infection in youths with celiac disease - A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33059041" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The Risk of Contracting COVID-19 Is Not Increased in Patients With Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33628059" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Risk of Severe Covid-19 in Patients with Celiac Disease: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27644734" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28067823" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Biomarkers to Monitor Gluten-Free Diet Compliance in Celiac Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31866245" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Most Patients With Celiac Disease on Gluten-Free Diets Consume Measurable Amounts of Gluten.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15191509" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24137038" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : An orthodontic retainer preventing remission in celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29057833" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Indications and Use of the Gluten Contamination Elimination Diet for Patients with Non-Responsive Celiac Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738465" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10840307" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : All that scallops is not celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33010252" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : AGA Clinical Practice Update on the Evaluation and Management of Seronegative Enteropathies: Expert Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/669218" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Celiac sprue and refractory sprue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7549032" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Dermatitis herpetiformis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947207" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
